Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$7.22 USD
-0.10 (-1.37%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $7.20 -0.02 (-0.28%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.22 USD
-0.10 (-1.37%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $7.20 -0.02 (-0.28%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Zacks News
Inovio Pharmaceuticals Initiates Dosing in HIV Vaccine Study
by Zacks Equity Research
Inovio Pharmaceuticals (INO) doses the first patient in a phase I/II study, which will evaluate its HIV vaccine Pennvax-GP's ability to bring about remission of HIV.
Inovio (INO) Q2 Loss Narrows, Revenues Surpass Estimates
by Zacks Equity Research
Inovio's (INO) Q2 loss betters estimates. Also, the company rides high on revenue beat.
Inovio Pharmaceuticals (INO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inovio (INO) delivered earnings and revenue surprises of 77.14% and 1050.54%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Inovio (INO) This Earnings Season?
by Zacks Equity Research
During Inovio's (INO) second-quarter 2018 earnings call, investor focus will remain on the company's progress with its lead candidate VGX-3100.
Inovio (INO) Down 5.8% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inovio Pharmaceuticals (INO) in Focus: Stock Moves 5.7% Higher
by Zacks Equity Research
Inovio Pharmaceuticals (INO) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
What's in the Cards for Inovio (INO) This Earnings Season?
by Zacks Equity Research
Inovio's (INO) most advanced pipeline candidate, VGX-3100's progress remains in focus. However, lack of an approved product in the company's portfolio is a dampener.
Why Is Inovio (INO) Up 6.6% Since Its Last Earnings Report?
by Zacks Equity Research
Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in the Cards for Inovio (INO) This Earnings Season?
by Zacks Equity Research
Inovio's (INO) most advanced pipeline candidate, VGX-3100's consistent progress might drive the stock in Q4. However, lack of an approved product in the company's portfolio is a dampener.
Inovio's Influenza Vaccine Shows Potential, Shares Rally
by Zacks Equity Research
Inovio Pharmaceuticals' (INO) universal influenza vaccine leads to broad protective antibody responses against all major deadly strains of H1 virus.
3 Stocks Under $10 That Surged Today
by Benjamin Rains
Here at Zacks, we encourage investors to follow our proven stock-picking system, which places a great deal of emphasis on the importance of earnings estimate revisions in order to identify winning stocks. However, we also always look to cover stocks, from S&P 500 powers to small cap-firms, when they make newsworthy moves.
Inovio Amends Chinese Deal for Immunotherapy, Shares Up
by Zacks Equity Research
Inovio (INO) entered into an amended agreement with ApolloBio Corporation and grants ApolloBio the exclusive right to develop and commercialize VGX-3100 within Greater China.
Inovio (INO) Down 15.5% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Inovio (INO) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in the Cards for Merck KGaA (MKGAF) in Q3 Earnings?
by Zacks Equity Research
Merck's (MKGAF) Healthcare and Life Science segments are expected to drive third-quarter sales. The company is progressing with its oncology drug, Bavencio and is also focusing on streamlining its business.
5 Biotech Stocks Well Poised to Surpass Expectations in Q3
by Zacks Equity Research
The pharma and biotech industry has demonstrated strength
Puma (PBYI) Q3 Earnings: Will it Surpass Estimates Again?
by Zacks Equity Research
Puma Biotechnology's (PBYI) only marketed product, Nerlynx (neratinib), for advanced breast cancer was launched in August. So Q3 is the first quarter in which Puma will record sales for Nerlynx.
BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
BioDelivery Sciences (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact third-quarter results remains to be seen.
Inovio Initiates Bladder Cancer Study With Roche's Tecentriq
by Zacks Equity Research
Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.
Surging Earnings Estimates Signal Good News for Inovio (INO)
by Zacks Equity Research
Inovio Pharmaceuticals (INO) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.
Inovio (INO) Q2 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Inovio Pharmaceuticals' (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q2. However, lack of an approved product in portfolio is a dampener.
Why Is Inovio (INO) Up 21.3% Since the Last Earnings Report?
by Zacks Equity Research
Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inovio (INO) Stock Rises on Encouraging HIV Vaccine Data
by Zacks Equity Research
Inovio Pharmaceuticals Inc. (INO) shares have rallied 12% since the company announced that its HIV vaccine evoked almost 100% immune response rates in a clinical study
What's in the Cards for Inovio (INO) This Earnings Season?
by Zacks Equity Research
Inovio Pharmaceuticals, Inc. (INO) is scheduled to report first-quarter 2017 results, after market closes. The company incurred wider-than-expected loss in the last quarter.
Why Is Inovio (INO) Down 2% Since the Last Earnings Report?
by Zacks Equity Research
Inovio Pharmaceuticals (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inovio (INO): What's in the Cards this Earnings Season?
by Zacks Equity Research
Inovio Pharmaceuticals, Inc. (INO) is expected to report fourth-quarter 2016 results this month. The company incurred wider-than-expected loss in the last quarter.